Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06963047 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluation of Blood Loss After Cesarean Delivery Via US Compared to Standard Care

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from May 1, 2026 to May 1, 2027
    • Study completion pushed from Jun 1, 2026 to Jun 1, 2027
    v4
  2. Primary endpoint revised
    • Secondary endpoints: 17 to 18
    v3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of May 1, 2025 to May 8, 2025
    • Site details revised
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Postpartum hemorrhage and anemia are considered a major health concern due to their impact on maternal morbidity and mortality, quality of life, and maternal cognitive and emotional functioning after delivery, which are particularly important during the critical period of mother-child bonding. Hemoglobin levels in the first 24 hours after delivery do not reflect the lowest point (nadir). The postpartum nadir occurs 48-72 hours after delivery due to the initial redistribution of plasma volume. The aim of this study was to examine whether postpartum ultrasound examination precedes laboratory test results in the diagnosis of anemia due to blood loss after cesarean section.
Trial Details
NCT Number NCT06963047
Lead Sponsor Holy Family Hospital, Nazareth, Israel
Conditions
(from sponsor)		 Postpartum Period
Related terms Hemoperitoneum, Postpartum Hemorrhage
Enrollment 276 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov